Loading...
•
Jun 30
Aeterna Zentaris Q2 2025 Earnings Report
Aeterna Zentaris, now operating as COSCIENS Biopharma, reported increased revenue and higher net loss in Q2 2025 due to restructuring and merger-related activities.
Key Takeaways
COSCIENS Biopharma posted $2.7 million in revenue for Q2 2025, with a net loss of $2.4 million driven by integration and restructuring efforts. The company reduced operating expenses by 28% and completed a strategic review of its pipeline while preparing to delist from Nasdaq.
Revenue for Q2 2025 was $2.7 million, up from $2.3 million YoY.
Net loss rose to $2.4 million due to merger and restructuring costs.
Operating expenses declined by 28% compared to Q2 2024.
Cash balance stood at $9.3 million at quarter-end.
Aeterna Zentaris
Aeterna Zentaris
Forward Guidance
COSCIENS aims to achieve long-term growth through portfolio optimization, ongoing cost controls, and completion of its Phase 2a study while transitioning off Nasdaq.
Positive Outlook
- Completed Phase 1 trial for AvenActive with no major safety issues.
- Phase 2a AvenActive study expected to conclude in Q3 2025.
- Board and CEO restructuring to drive operational efficiency.
- Macrilen pediatric strategy under FDA review with Type C meeting planned.
- Zero-based budgeting and cost reductions expected to realize full savings in 2026.
Challenges Ahead
- Company will voluntarily delist from Nasdaq, reducing U.S. investor access.
- Restructuring efforts include 27% workforce reduction.
- Phase 3 DETECT trial for Macrilen failed to meet primary endpoint.
- No direct-to-consumer platform limits immediate commercialization.
- Cash position remains modest amid ongoing clinical and operational activities.